Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer

PURPOSE: Third-generation epidermal growth factor receptor (EGFR) inhibitors like nazartinib are active against EGFR mutation–positive lung cancers with T790M-mediated acquired resistance to initial anti-EGFR treatment, but some patients have mixed responses. METHODS: Multiple serial tumor and liqui...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JCO Precis Oncol
Autors principals: Piotrowska, Zofia, Hazar-Rethinam, Mehlika, Rizzo, Coleen, Nadres, Brandon, Van Seventer, Emily E., Shahzade, Heather A., Lennes, Inga T., Iafrate, Anthony J., Dias-Santagata, Dora, Leshchiner, Ignaty, Jessop, Nicholas A., Hu, Haichuan, Digumarthy, Subba R., Nagy, Rebecca J., Lanman, Richard B., Moody, Susan, Niederst, Matthew J., Engelman, Jeffrey A., Hata, Aaron N., Corcoran, Ryan B., Sequist, Lecia V.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2018
Matèries:
Original Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6097183/
https://ncbi.nlm.nih.gov/pubmed/30123863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.17.00263
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars